Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Blood (2019) 134 (Supplement_1): 247.

https://doi.org/10.1182/blood-2019-131024

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Craig W. Freyer, PharmD, Alex Ganetsky, PharmD, Colleen Timlin, PharmD, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alexander E. Perl, MD, Selina Luger, MD, Jacqueline Smith, MSN, CRNP, Edward Stadtmauer, David L. Porter, MD

Blood (2018) 132 (Supplement 1): 5696.

https://doi.org/10.1182/blood-2018-99-111550

Published: 2018

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Katherine D Cummins, BMBS, Noelle Frey, MD, Anne Marie Nelson, Aliza Schmidt, MS, Selina Luger, MD FRCPC, Randi E. Isaacs, MD, Simon F Lacey, PhD BS, Elizabeth Hexner, MDMS, J. Joseph Melenhorst, PhD, Carl H June, MD, David L Porter, MD, Saar I Gill, MD PhD

Blood (2017) 130 (Supplement 1): 1359.

https://doi.org/10.1182/blood.V130.Suppl_1.1359.1359

Published: 2017

Journal Articles

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Marco Ruella, MD, David M. Barrett, Olga Shestova, PhD, Jessica Perazzelli, PhD, Avery D. Posey, PhD, Miroslaw Kozlowski, PhD, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 4463.

https://doi.org/10.1182/blood.V130.Suppl_1.4463.4463

Published: 2017

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Blood (2017) 130 (Supplement 1): 653.

https://doi.org/10.1182/blood.V130.Suppl_1.653.653

Published: 2017

Journal Articles

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Blood (2016) 128 (22): 281.

https://doi.org/10.1182/blood.V128.22.281.281

Published: 2016

Journal Articles

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Michael Klichinsky, PharmD, Miriam Y Kim, MD, Craig Soderquist, MD, Adam Bagg, MD, Reshma Singh, PhD, Celeste Richardson, PhD, Regina M Young, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 766.

https://doi.org/10.1182/blood.V128.22.766.766

Published: 2016

Journal Articles

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Saad S Kenderian, MD, Marco Ruella, MD, Olga Shestova, PhD, Miriam Y Kim, MD, Michael Klichinsky, PharmD, Fang Chen, PhD, Natalka Kengle, Simon Francis Lacey, PhD BS, J. Joseph Melenhorst, PhD, Carl H June, MD, Saar I. Gill, MD PhD

Blood (2016) 128 (22): 652.

https://doi.org/10.1182/blood.V128.22.652.652

Published: 2016

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 966.

https://doi.org/10.1182/blood.V124.21.966.966

Published: 2014

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Taylor Chen, John Scholler, Mariusz A. Wasik, MD, Carl H. June, MD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 806.

https://doi.org/10.1182/blood.V124.21.806.806

Published: 2014

Journal Articles

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

Alexis Zebrowski, BA, Alexandra Hanlon, PhD, James Mangan, MD PhD, Jennifer Pinto-Martin, PhD MPH, Selina M. Luger, MD, Alison W. Loren, MD, Elizabeth O Hexner, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 1239.

https://doi.org/10.1182/blood.V124.21.1239.1239

Published: 2014

Journal Articles

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Ran Reshef, MD, Austin P. Huffman, BA, Amy Gao, BA, Mary Sell, BS MT(ASCP), Marlise R. Luskin, MD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Sunita Dwivedy Nasta, MD, Noelle V. Frey, MDMS, Saar I. Gill, MD PhD, James Mangan, MD PhD, Lee P. Richman, BA, Taku Kambayashi, MDPhD, Edward A. Stadtmauer, MD, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 1260.

https://doi.org/10.1182/blood.V124.21.1260.1260

Published: 2014

Journal Articles

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Anita J. Kumar, MDMS, Pavel Vassilev, BS, Alison W. Loren, MDMS, Selina M. Luger, MD, Ran Reshef, MD, Saar I. Gill, MD PhD, Jacqueline Smith, CRNP, Steven C. Goldstein, MD, Elizabeth Hexner, MD, Edward A. Stadtmauer, MD, David Porter, MD, Noelle V. Frey, MDMS

Blood (2014) 124 (21): 3946.

https://doi.org/10.1182/blood.V124.21.3946.3946

Published: 2014

NARROW

Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

A Cellular Antidote to Specifically Deplete Anti-CD19 Chimeric Antigen Receptor (CAR19) Positive Cells

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Pilot Study of Non-Viral, RNA-Redirected Autologous Anti-CD19 Chimeric Antigen Receptor Modified T-Cells in Patients with Refractory/Relapsed Hodgkin Lymphoma (HL)

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR

Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor T Cells

Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Novel Chimeric Antigen Receptor T Cells for the Treatment of Hodgkin Lymphoma

Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant

CD8 Cell Dose in Peripheral Blood Stem-Cell Grafts Correlates with Relapse and Survival after Reduced Intensity Allogeneic Stem-Cell Transplantation

Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only